Status:
UNKNOWN
Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Lead Sponsor:
Samsung Medical Center
Conditions:
Depression
Antidepressant Drug Adverse Reaction
Eligibility:
All Genders
25-85 years
Phase:
NA
Brief Summary
The Purpose of this study is to predict antidepressant response in advance using pharmacogenomics and peripheral biological markers in depressed patients.
Detailed Description
The difficulties to treat depressed patients are 1)the patients don't respond to antidepressant is about 40% of which, and 2) The time lag is existed until the patients respond to antidepressant and s...
Eligibility Criteria
Inclusion
- 25 \< age \<85
- major depressed patients satisfied with the diagnosis criteria depression of DSM-IV
- interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians
Exclusion
- received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks
- potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2018
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00817011
Start Date
April 1 2006
End Date
March 1 2018
Last Update
December 31 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Kangnam, Seoul, South Korea, 135-710